Risk factors and drug resistance in early-onset neonatal group B streptococcal disease.
- Author:
Ying-Wei WANG
1
;
Yao-Qiang DU
2
;
Xiao-Lin MIAO
3
;
Guang-Yong YE
4
;
Yi-Yun WANG
4
;
Ai-Bo XU
2
;
Yun-Zhong JING
2
;
Yu TONG
5
;
Kai XU
5
;
Mei-Qin ZHENG
3
;
Dong CHEN
6
;
Zhen WANG
2
Author Information
- Publication Type:Journal Article
- Keywords: Neonate; Group B streptococcus; Risk factor; Drug-resistance
- MeSH: Adult; Anti-Bacterial Agents/therapeutic use*; China/epidemiology*; Drug Resistance; Drug Resistance, Bacterial; Female; Humans; Incidence; Mothers; Parity; Pregnancy; Pregnancy Complications, Infectious/diagnosis*; Risk Factors; Streptococcal Infections/drug therapy*; Streptococcus agalactiae
- From: Journal of Zhejiang University. Science. B 2018;19(12):973-978
- CountryChina
- Language:English
- Abstract: In recent years, group B streptococcus (GBS) has become an important pathogen that causes infections in many neonatal organs, including the brain, lung, and eye (Ballard et al., 2016). A series of studies performed on GBS infections in western countries have revealed that GBS is one of the primary pathogens implicated in perinatal infection, and GBS infections are a major cause of neonatal morbidity and mortality in the United States (Decheva et al., 2013). In China, GBS is mainly found by screens for adult urogenital tract and perinatal infections, and neonatal GBS infections have been rarely reported. The incidence rate of early-onset neonatal GBS disease is thought to be lower in China than in western countries; however, this data is controversial since it also reflects the clinical interest in GBS (Dabrowska-Szponar and Galinski, 2001).
